MRVI
Maravai LifeSciences Holdings, Inc.
$7.44
Stable Earnings Power
40%
P/Adj-EPS × Normalized Multiple
Strong
·
Conviction
Overvalued
Trading 94.5% above fair value
You pay
$7.44
Bear
$3.28
Fair
$3.83
Bull
$4.37
Bear
$3.28
-55.9%
$0.27 × 12x P/E
Fair
$3.83
-48.6%
$0.27 × 14x P/E
Bull
$4.37
-41.2%
$0.27 × 16x P/E
Adjust Assumptions
14.0x
0.27$
Key Value Driver
Normalized P/E multiple (14x base case)
Implied Market Multiple
27.2x
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (14 analysts)
$7.00
Divergence from AlphaVal
45%
Summary
Applying a 14x P/E to adjusted EPS of $0.27, the base-case value is $3.83 per share.
Warnings
Wall Street's average price target is $7.00 (from 14 analysts). Our estimate is 45% below the consensus -- consider that gap carefully.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples